Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Up 68.7% in July

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totaling 8,827 shares, a growth of 68.7% from the July 15th total of 5,232 shares. Based on an average daily trading volume, of 4,750 shares, the days-to-cover ratio is currently 1.9 days. Approximately 0.3% of the company’s stock are short sold.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PBE. Raymond James Financial Inc. grew its position in Invesco Biotechnology & Genome ETF by 1.8% during the third quarter. Raymond James Financial Inc. now owns 8,078 shares of the company’s stock worth $564,000 after buying an additional 141 shares in the last quarter. NewEdge Advisors LLC raised its holdings in Invesco Biotechnology & Genome ETF by 18.1% in the 4th quarter. NewEdge Advisors LLC now owns 1,043 shares of the company’s stock valued at $86,000 after acquiring an additional 160 shares in the last quarter. Comerica Bank lifted its position in shares of Invesco Biotechnology & Genome ETF by 86.2% during the 4th quarter. Comerica Bank now owns 378 shares of the company’s stock valued at $31,000 after acquiring an additional 175 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Invesco Biotechnology & Genome ETF by 74.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock valued at $40,000 after acquiring an additional 245 shares during the period. Finally, Compass Financial Management LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF during the 2nd quarter worth $27,000.

Invesco Biotechnology & Genome ETF Trading Up 1.0%

Shares of NYSEARCA PBE traded up $0.98 during mid-day trading on Monday, hitting $94.72. The company had a trading volume of 7,043 shares, compared to its average volume of 12,884. The company has a market capitalization of $298.37 million, a PE ratio of 20.44 and a beta of 0.70. The firm has a 50-day simple moving average of $89.71 and a two-hundred day simple moving average of $83.84. Invesco Biotechnology & Genome ETF has a one year low of $67.41 and a one year high of $95.01.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.